Publications by authors named "H Rabezanahary"
Background: Measuring the ability of SARS-CoV-2 antibodies to neutralize live viruses remains an effective approach to quantify the level of protection of individuals. We assessed the neutralization activity against the ancestral SARS-CoV-2, Delta, Omicron BA.1, BA.
View Article and Find Full Text PDFWhile liver inflammation is associated with AIDS, little is known so far about hepatic CD4 T cells. By using the simian immunodeficiency virus (SIV)-infected rhesus macaque (RM) model, we aimed to characterize CD4 T cells. The phenotype of CD4 T cells was assessed by flow cytometry from uninfected ( = 3) and infected RMs, with either SIVmac251 ( = 6) or SHIVSF162p3 ( = 6).
View Article and Find Full Text PDFArticle Synopsis
- Identifying immune cells and tissues is crucial for understanding how HIV-1 hides in the body, which is key for cure research.
- Rhesus macaques with SIV infections were studied to see how viruses spread in the liver and lungs, revealing that untreated animals showed more inflammation and immune responses.
- Early antiretroviral therapy (ART) significantly reduced viral spread and inflammation, indicating that starting treatment early helps minimize viral reservoirs.
- After stopping ART, some viral DNA was found in specific immune cells, highlighting the risk of viral rebound if treatment is interrupted.
Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals.
View Article and Find Full Text PDFA vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants.
View Article and Find Full Text PDF